B. Oyan Et Al. , "Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.," 45th Annual Meeting of the American-Society-of-Hematology , vol.102, SAN DIEGO, CALIFORNIA, 2003
Oyan, B. Et Al. 2003. Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.. 45th Annual Meeting of the American-Society-of-Hematology , (SAN DIEGO, CALIFORNIA).
Oyan, B., Koc, Y., Kars, A., Turker, A., Tekuzman, G., & Kansu, E., (2003). Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. . 45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA
Oyan, BAŞAK Et Al. "Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.," 45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 2003
Oyan, BAŞAK O. Et Al. "Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.." 45th Annual Meeting of the American-Society-of-Hematology , SAN DIEGO, CALIFORNIA, 2003
Oyan, B. Et Al. (2003) . "Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.." 45th Annual Meeting of the American-Society-of-Hematology , SAN DIEGO, CALIFORNIA.
@conferencepaper{conferencepaper, author={BAŞAK OYAN ULUÇ Et Al. }, title={Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.}, congress name={45th Annual Meeting of the American-Society-of-Hematology}, city={SAN DIEGO}, country={CALIFORNIA}, year={2003}}